Agfa-Gevaert N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AFGVF research report →
Price Chart
About the company
Agfa-Gevaert N. V. operates as a global developer, manufacturer, and distributor of a wide array of analog and digital imaging systems, alongside advanced IT solutions.
- CEO
- Pascal Juery
- IPO
- 2009
- Employees
- 4,256
- HQ
- Mortsel, VL, BE
Get TickerSpark's AI analysis on AFGVF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $88.40M
- P/E
- -0.44
- Fwd P/E
- 16.47
- PEG
- 0.01
- P/S
- 0.05
- P/B
- 0.24
- EV/EBITDA
- 1.68
- Div Yield
- 0.00%
- Gross Margin
- 29.41%
- Op Margin
- 6.82%
- Net Margin
- -11.00%
- ROE
- -48.24%
- ROIC
- 8.21%
Latest fiscal year · YoY change
- Revenue
- $1.09B-4.6%
- Gross Profit
- $327.88M-7.4%
- Op Income
- $-10,995,880
- Net Income
- $-70,973,407+22.9%
- EPS
- $-0.46+23.3%
- OCF Growth
- +1749.4%
- FCF Growth
- +165.3%
- 52W High
- $1.16
- 52W Low
- $0.57
- 50D MA
- $0.57
- 200D MA
- $0.57
- Beta
- 0.60
- RSI (14)
- 0
- Avg Volume
- 544
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Agfa said its transformation remains on track, with strong HealthCare IT momentum and DPS set for an EFI combination, but Q3 continuing operations were weak and cash remained under pressure from restructuring and silver volatility.· November 10, 2026
- Q3 continuing revenue was flat year over year at EUR 210 million, while adjusted EBITDA fell from EUR 4 million to EUR 1 million.
- HealthCare IT was the bright spot, with sales up 11%, order intake up 21% over the last 12 months, and cloud orders more than tripled.
- Imaging and Advanced Materials was softer, hurt by lower volumes, DR reorganization, and silver-related accounting/timing effects.
- The company said savings are on track at EUR 64 million, but cash burn continues due to transformation costs and pension obligations.
- Net debt/covenants stayed within limits, with leverage at 1.9x versus a 3.0x covenant maximum and liquidity headroom of just under EUR 96 million.
Q3 continuing revenue was flat year over year at EUR 210 million. Adjusted EBITDA declined from EUR 4 million in Q3 2025 to EUR 1 million in Q3 2026, and the segment margin moved from 18.7% to 15.8% in-quarter, though management said year-to-date segment gross margin was essentially flat at 20.6% versus 20.7%. Year-to-date sales were EUR 631 million versus EUR 647 million last year, while year-to-date EBITDA was EUR 25 million versus EUR 22 million last year. Cash flow in the quarter was minus EUR 14 million, and adjusted free cash flow was EUR 8 million. Management said savings totaled EUR 64 million. For the outlook, HealthCare IT profitability is expected to be slightly below last year because the cloud transition is accelerating faster than assumed, with a more meaningful EBITDA inflection expected in 2028; Imaging and Advanced Materials is expected to be below last year overall; DPS is expected to make up Q3’s weaker equipment sales in Q4; and group cash flow is expected to remain more negative than last year because of prior-year AgfaPhoto cash-in, higher restructuring cash-out, and silver volatility.
Pascal Juery framed the quarter as another step in Agfa’s broader transformation rather than a standalone result. He emphasized that the cloud shift in HealthCare IT is accelerating, that the business is adding new logos, and that the transition should ultimately create a stronger subscription franchise even if it pressures short-term profitability. He was also constructive on DPS ahead of the EFI combination and said Green Hydrogen should rebound in 2027, while Film and Chemicals remains a cash-generating business despite volatility.
Declan Guerin focused on the mechanics behind the quarter’s numbers: flat revenue, EBITDA down to EUR 1 million, and quarter cash flow of minus EUR 14 million driven mainly by transformation-related cash-outs. He highlighted that year-to-date sales were EUR 631 million versus EUR 647 million, year-to-date EBITDA was EUR 25 million versus EUR 22 million, and leverage ended at 1.9x against a 3.0x covenant maximum, with interest cover at 8.6x and liquidity headroom just under EUR 96 million. He also explained that silver caused timing noise, citing 9M sales impact of plus EUR 45 million, gross margin impact of plus EUR 5 million, and cash impact of just over minus EUR 30 million, and said the RCF was extended to August 1, 2030.
Analysts pressed management on when HealthCare IT’s SaaS transition would become EBITDA-accretive, when the remaining business could become sustainably free cash flow positive, and whether more radical restructuring was needed in underperforming assets. Management said 2028 should be the year of a meaningful EBITDA inflection in HealthCare IT, with long-term EBITDA margins potentially in the 20% to 25% range, but stressed 2027 will still be affected by the cloud transition. On cash generation, management said the next couple of years remain transformation years because restructuring and pensions will continue to absorb cash. On Green Hydrogen, management reiterated that 2027 should see a rebound because project visibility is already improving, and said film restructuring has already been significant, with further productivity measures to follow rather than another major overhaul.
The strongest bullish point is that HealthCare IT appears to be gaining real commercial traction, with 21% rolling order growth, cloud orders more than tripled, and a rising recurring revenue mix. Management also sounded confident that the cloud transition will ultimately improve the business, with 2028 framed as the year of margin inflection and long-term EBITDA margins potentially above 20%. DPS is also described as entering the EFI combination from a position of profitable growth, and Green Hydrogen is expected to rebound in 2027.
The main risk is that short-term financial performance remains weak: Q3 EBITDA fell sharply, cash flow was negative, and management expects cash burn to continue through the transformation period. HealthCare IT’s stronger growth is coming with near-term margin pressure because cloud revenue is recognized over time instead of upfront, while Imaging and Advanced Materials is still under pressure from DR reorganization, weak hydrogen activity, and silver-related volatility. Management also said the next couple of years will still be transformation years, implying restructuring and pension-related cash outflows are not done yet.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.9%
- Shares Outstanding
- 154.82M
- Float Shares
- 125.28M
Our AFGVF coverage
Recent articles, reports, and earnings notes.
No research on AFGVF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AFGVF report →Agfa-Gevaert delivers robust Q1 2026 performance amid market challenges
globenewswire.com · May 12
Agfa-Gevaert: Convening of Annual General Meeting
globenewswire.com · Apr 10
Agfa-Gevaert Group in 2025: strong Q4 profitability and free cash flow – good step-up in FY profitability in HealthCare IT and Digital Print & Chemicals
globenewswire.com · Mar 11
Agfa-Gevaert (OTCMKTS:AFGVF) Shares Down 50.8% – What’s Next?
defenseworld.net · Jan 13
Agfa-Gevaert NV (AFGVY) Q3 2025 Earnings Call Transcript
seekingalpha.com · Nov 13
Agfa-Gevaert NV signs new revolving credit facility - Regulated information - Contains inside information
globenewswire.com · Aug 1
Arbitral Tribunal acting under ICC Rules of Arbitration issues final award in an arbitration between Agfa-Gevaert and the insolvency receiver of AgfaPhoto GmbH
globenewswire.com · Jun 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.